-Jerry Chao Researcher Activity Profile

Research Author Detailed Information 

Jerry Chao Publication Rate By Year

Jerry Chao has published 1 paper(s) in 1977, 1 paper(s) in 1983, 1 paper(s) in 2006, 11 paper(s) in 2007, 9 paper(s) in 2008, for a total of 23 research publications in total.

Jerry J Chao Author Information

LAST NAME: chao

FIRST NAME: Jerry

INITIALS: j

AFFILIATION:

Papers

Jerry Chao's Publication Record

1. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Year Published: 2007
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
2. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Year Published: 2007
Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China.
3. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Year Published: 2006
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, South Carolina 29425, USA.
4. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Year Published: 2007
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA. chaol@musc.edu
5. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Year Published: 2007
Atherosclerosis Research Centre, Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China.
6. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Year Published: 2007
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425-2211, USA.
7. Upregulation of kallistatin expression in rheumatoid joints. Year Published: 2007
Section of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, No. 1 University Road, Tainan, Taiwan. wangcr@mail.ncku.edu.tw
8. Gene therapy for hypertension: a review of potential targets. Year Published: 2007
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA.
9. Improving medication adherence: the role of the health care delivery system and health care providers. Year Published: 2007
Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60041, USA jingdong.chao@abbott.com.
10. Improving medication adherence: the role of the health care delivery system and health care providers. Year Published: 2007
Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60041, USA. jingdong.chao@abbott.com
11. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Year Published: 2008
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425-2211, United States.
12. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists. Year Published: 2008
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. purakkattle.biju@spcorp.com
13. Improving medication adherence: the role of the health care delivery system and health care providers. Year Published: 2007
Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60041, USA. jingdong.chao@abbott.com
14. Upregulation of kallistatin expression in rheumatoid joints. Year Published: 2007
Section of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, No. 1 University Road, Tainan, Taiwan. wangcr@mail.ncku.edu.tw
15. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Year Published: 2008
Analysis Group, Inc., Boston, MA 02199, USA. ayu@analysisgroup.com
16. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Year Published: 2008
Analysis Group, Inc., Boston, MA 02199, USA. ayu@analysisgroup.com
17. The effects of aldosterone and spironolactone on renal kallikrein in the rat. Year Published: 1977
18. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists. Year Published: 2008
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. purakkattle.biju@spcorp.com
19. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists. Year Published: 2008
Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
20. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists. Year Published: 2008
Department of Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
21. Pathophysiology of the ciliary motility syndromes. Year Published: 1983
22. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Year Published: 2008
Department of Biology, Charleston Southern University, 9200 University Boulevard, Charleston, South Carolina 29406, USA. gbledsoe@csuniv.edu
23. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Year Published: 2008
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425-2211, USA.